EVIDENCE. COMPARISONS. CLEAR NEXT STEPS.FOR US CLINIC TEAMS PROCUREMENT RESEARCH
Next steps

Sources

Dose Diligence research deskSection 12 · Page 11 of 11Last updated 17 Nov 2026

Primary regulatory, court, programme and government sources used in this document are listed below. Supplier programme pages establish published terms and workflows, not independently audited capacity or service performance. Source review does not constitute a complete litigation search, facility audit or 50-state legal opinion.

  1. FDA — GLP-1 compounding policy clarification, including April 1, 2026 update: https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
  2. FDA — Drug Shortages database: https://www.accessdata.fda.gov/scripts/drugshortages/default.cfm
  3. US Court of Appeals for the Fifth Circuit — No. 25-10758, revised September 1, 2026: https://www.ca5.uscourts.gov/opinions/unpub/25/25-10758.0.pdf
  4. FDA — Proposed exclusion from the 503B bulks list, April 30, 2026: https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list
  5. FDA — Concerns with unapproved GLP-1 drugs: https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
  6. FDA — Registered Outsourcing Facilities; retrieved table updated November 6, 2026: https://www.fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities
  7. FDA — Compounding inspections, recalls and other actions: https://www.fda.gov/drugs/human-drug-compounding/compounding-inspections-recalls-and-other-actions
  8. FDA — Is It Really FDA Approved?: https://www.fda.gov/consumers/consumer-updates/it-really-fda-approved
  9. California State Board of Pharmacy — Licence verification: https://www.pharmacy.ca.gov/about/verify_lic
  10. FDA — Pharmacist DSCSA responsibilities: https://www.fda.gov/drugs/drug-supply-chain-security-act-dscsa/pharmacists-utilize-dscsa-requirements-protect-your-patients
  11. FDA — Small-business-dispenser exemption letter, August 6, 2026: https://www.fda.gov/media/194424/download
  12. LillyDirect — Healthcare-provider FAQ: https://www.lilly.com/lillydirect/hcp/faq
  13. NovoCare — Healthcare-provider home-delivery information: https://www.novocare.com/hcp/delivery.html
  14. CMS — Medicare GLP-1 Bridge information for pharmacies: https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge/information-pharmacies
  15. HHS — Business Associates Frequently Asked Questions: https://www.hhs.gov/hipaa/for-professionals/privacy/guidance/business-associates/index.html
  16. FDA — Outsourcing-facility registration questions and answers: https://www.fda.gov/drugs/human-drug-compounding/questions-and-answers-related-guidance-entities-considering-whether-register-outsourcing-facilities
  17. FDA — GLP-1 safety-labelling communication, November 9, 2026: https://www.fda.gov/drugs/drug-safety-communications/fda-requires-safety-labeling-changes-glucagon-peptide-1-receptor-agonists-glp-1-ras-due-potential

Sources cited on this page

  1. fda.gov · Source 1 ↗https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
  2. accessdata.fda.gov · Source 2 ↗https://www.accessdata.fda.gov/scripts/drugshortages/default.cfm
  3. ca5.uscourts.gov · Source 3 ↗https://www.ca5.uscourts.gov/opinions/unpub/25/25-10758.0.pdf
  4. fda.gov · Source 4 ↗https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list
  5. fda.gov · Source 5 ↗https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
  6. fda.gov · Source 6 ↗https://www.fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities
  7. fda.gov · Source 7 ↗https://www.fda.gov/drugs/human-drug-compounding/compounding-inspections-recalls-and-other-actions
  8. fda.gov · Source 8 ↗https://www.fda.gov/consumers/consumer-updates/it-really-fda-approved
  9. pharmacy.ca.gov · Source 9 ↗https://www.pharmacy.ca.gov/about/verify_lic
  10. fda.gov · Source 10 ↗https://www.fda.gov/drugs/drug-supply-chain-security-act-dscsa/pharmacists-utilize-dscsa-requirements-protect-your-patients
  11. fda.gov · Source 11 ↗https://www.fda.gov/media/194424/download
  12. lilly.com · Source 12 ↗https://www.lilly.com/lillydirect/hcp/faq
  13. novocare.com · Source 13 ↗https://www.novocare.com/hcp/delivery.html
  14. cms.gov · Source 14 ↗https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge/information-pharmacies
  15. hhs.gov · Source 15 ↗https://www.hhs.gov/hipaa/for-professionals/privacy/guidance/business-associates/index.html
  16. fda.gov · Source 16 ↗https://www.fda.gov/drugs/human-drug-compounding/questions-and-answers-related-guidance-entities-considering-whether-register-outsourcing-facilities
  17. fda.gov · Source 17 ↗https://www.fda.gov/drugs/drug-safety-communications/fda-requires-safety-labeling-changes-glucagon-peptide-1-receptor-agonists-glp-1-ras-due-potential
Section sources →